bioAffinity Technologies Inc Overview
Industry: Diagnostics & Research
Sector: Healthcare
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas. bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other d Read MoreMavefund brings filings, fundamentals, valuation, price history and news for bioAffinity Technologies Inc into one research view. The sections below show what strengthens or weakens the research case.
Score
Reported Results
What the company reported, with filing details kept small.
Quarterly result summary
Revenue was $1.5M (reported). Net loss was -$3.4M (from $4.1M). G&A expense was $2.9M.
Revenue
$1.5M
reported
Net loss
-$3.4M
from $4.1M
G&A expense
$2.9M
reported
Cash
$2.4M
reported
What changed
- Revenue reported to $1.5M.
- Net loss was -$3.4M (from $4.1M).
Guidance / outlook
No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.
Earnings release
Open filing
Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.
Other recent earnings materials
SEC filing
8-K
Aug 07, 2026
SEC filing
10-Q
Aug 07, 2026
SEC filing
10-Q
May 11, 2026
SEC filing
8-K
May 08, 2026
SEC filing
10-K
Mar 16, 2026
Earnings release
Earnings release
Mar 13, 2026
SEC filing
8-K
Mar 13, 2026
Earnings release
Earnings release
Nov 14, 2025
SEC filing
10-Q
Nov 14, 2025
SEC filing
8-K
Nov 14, 2025
SEC filing
10-Q
Aug 14, 2025
Prediction-grade evidence
Recent News
Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.
bioAffinity Technologies earnings beat by $1.46, revenue fell short of estimates
Headline from Investing.com: bioAffinity Technologies earnings beat by $1.46, revenue fell short of estimates.
bioAffinity Technologies closes $4M private placement
Headline from Investing.com: bioAffinity Technologies closes $4M private placement.
WallachBeth Capital Announces Closing of bioAffinity Technologies $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
Headline from PR Newswire: WallachBeth Capital Announces Closing of bioAffinity Technologies $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules.
bioAffinity Technologies closes $4M private placement By Investing.com
Headline from Investing.com Canada: bioAffinity Technologies closes $4M private placement By Investing.com.
bioAffinity Technologies prices $4M private placement offering
Headline from Investing.com: bioAffinity Technologies prices $4M private placement offering.
WallachBeth Capital Announces bioAffinity Technologies Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
Headline from PR Newswire: WallachBeth Capital Announces bioAffinity Technologies Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules.
Earnings Per Share
Score 0.00/5
bioAffinity Technologies Inc earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
In
Diagnostics & Research industry
, IQVIA Holdings Inc
, Agilent Technologies Inc
, Thermo Fisher Scientific Inc
are companies with high ratings.
Return on Equity
Score 3.45/5
bioAffinity Technologies Inc stands out with a superior score in the Return on Equity (ROE) section, surpassing the sector median value and showcasing its strong performance in this metric. The top companies in the same sector include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
Metric chart temporarily unavailable.
Net Margin
Score 4.24/5
bioAffinity Technologies Inc
commands a high score, propelled by its net margin consistently outpacing the sector median value and exhibiting continuous growth in recent six years; noteworthy counterparts in the sector, boasting similarly high scores, include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
Metric chart temporarily unavailable.
Leverage
Score 4.94/5
bioAffinity Technologies Inc
attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
, also exhibit high scores.
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
Metric chart temporarily unavailable.
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Verified SEC statements load when this section enters view.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.
Financial Ratio
Yearly
Quarterly
Financial
Profitability
Growth
Cash Flow
Financial Health
Efficiency Ratios